Business
Alto Neuroscience is a clinical-stage biopharmaceutical company using a precision psychiatry platform to develop neuropsychiatric treatments tied to brain-based biomarkers.
Alto Neuroscience remained pre-revenue, the net loss widened slightly to $63.2M, and free cash flow was -$51.8M.
The read at a glance✓ Audited against SEC data
- Business mix — Precision psychiatry pipelineNote
- Revenue — No standard revenue fieldNote
- Profitability — Net loss widened 2.9%Watch
- Cash — Free cash flow was -$51.8MWatch
- Balance sheet — Equity was roughly flat; debt roseNote
- Insiders — 0 buys / 0 sellsNote
- Accounting — Forensic screen unavailableNote
Leadership changes
From Alto Neuroscience, Inc.'s own filings, the day they're filed.
- Andrew Miller · directors · appointmenteff. 2026-03-16
- Michael Hanley · Chief Operating Officer · appointmenteff. 2024-05-20
- Christopher Nixon Cox · President · appointment
Latest filings
- 8-K · Company announcement2026-08-27
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-07-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Alto Neuroscience, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.